TDP-43 in Cerebrospinal Fluid of Patients With Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Open Access
- 31 October 2008
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 65 (11), 1481-1487
- https://doi.org/10.1001/archneur.65.11.1481
Abstract
Background: Recently, TAR DNA-binding protein 43 (TDP-43) was identified as the major component of ubiquitin-positive tau-negative neuronal and glial inclusions in the most common form of frontotemporal lobar degeneration (FTLD) and in amyotrophic lateral sclerosis (ALS). It was demonstrated that different TDP-43 profiles correspond to clinical phenotypes of FTLD or ALS subgroups, and the differential diagnostic potential of TDP-43 was suggested. Objectives: To examine TDP-43 in cerebrospinal fluid (CSF) and to analyze whether it could serve as a diagnostic marker. Design: We characterized CSF TDP-43 by immuno-blot using different TDP-43 antibodies and determined the relative TDP-43 levels in CSF samples from patients. Setting: Academic research. Patients: Twelve patients with FTLD, 15 patients with ALS, 9 patients with ALS plus FTLD, 3 patients with ALS plus additional signs of frontal disinhibition, and 13 control subjects. Main Outcome Measures: Results of TDP-43 immunoblot. Results: Polyclonal TDP-43 antibodies recognized a 45-kDa band in all analyzed samples. Two monoclonal and N-terminus-specific antibodies did not detect any specific bands, but C-terminus-specific antibodies detected a 45-kDa band and additional bands at approximately 20 kDa in all CSF samples. Relative quantification of 45-kDa bands revealed significant differences among the diagnostic groups (P=.046). Specifically, patients with ALS (P=.03) and FTLD (P=.02) had higher TDP-43 levels than controls but with a prominent overlap of values. Conclusion: Although there is no evidence of pathologically altered TDP-43 proteins in CSF, TDP-43 levels in CSF might aid in characterizing subgroups of patients across the ALS and FTLD disease spectrum.Keywords
This publication has 33 references indexed in Scilit:
- TDP‐43 A315T mutation in familial motor neuron diseaseAnnals of Neurology, 2008
- Pathological TDP‐43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutationsAnnals of Neurology, 2007
- Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementiasMolecular Psychiatry, 2007
- Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerationsJournal of Neural Transmission, 2007
- TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosisBiochemical and Biophysical Research Communications, 2006
- Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral SclerosisScience, 2006
- Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's diseaseAnnals of Neurology, 2005
- Preclinical Trials – An Update on Translational Research in ALSNeurodegenerative Diseases, 2005
- Total and Phosphorylated Tau Proteins: Evaluation as Core Biomarker Candidates in Frontotemporal DementiaDementia and Geriatric Cognitive Disorders, 2004
- Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based studyBrain, 2003